Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism

Journal of Clinical Investigation

Volumn 117, Issue 11, 2007, Pages 3583-3592

  Van Herwaarden, Antonius E ^a   Wagenaar, Els ^a   Van Der Kruijssen, Cornelia M M ^a   Van Waterschoot, Robert A B ^a   Smit, Johan W ^b   Song, Ji Ying ^a   Van Der Valk, Martin A ^a   Van Tellingen, Olaf ^a   Van Der Hoorn, José W A ^c   Rosing, Hilde ^d   Beijnen, Jos H ^d   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DOCETAXEL; METHOXYFLURANE; RITONAVIR; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYP3A GENE; DETOXIFICATION; DISEASE MODEL; DRUG CLEARANCE; ENZYME ANALYSIS; FIRST PASS EFFECT; GENE; INTESTINE EPITHELIUM; KNOCKOUT GENE; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SPECIFICITY; XENOBIOTIC METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSOMES; PHENOTYPE; TAXOIDS; XENOBIOTICS;

EID: 36049034219     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33435     Document Type: Article

References (28)

1. Guengerich, F.P. 1999. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39:1-17.
2. Kitada, M., Kamataki, T., Itahashi, K., Rikihisa, T., and Kanakubo, Y. 1987. P-450 HFLa, a form of Cytochrome P-450 purified from human fetal livers, is the 16α-hydroxylase of dehydroepiandrosterone 3-sulfate. J. Biol. Chem. 262:13534-13537.
3. Givens, R.C., et al. 2003. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J. Appl. Physiol. 95:1297-1300.
4. Ho, H., et al. 2005. Association between the CYP3A5 genotype and blood pressure. Hypertension. 45:294-298.
5. Grogan, W.M., Phillips, V.M., Schuetz, E.G., Guzelian, P.S., and Watlington, C.O. 1990. Corticosterone 6 beta-hydroxylase in A6 epithelia: a steroid-inducible cytochrome P-450. Am. J. Physiol. 258:C480-C488.
6. Koch, I., et al. 2002. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos. 30:1108-1114.
7. Lamba, J.K., Lin, Y.S., Schuetz, E.G., and Thummel, K.E. 2002. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54:1271-1294.
8. Dresser, G.K., Spence, J.D., and Bailey, D.G. 2000. Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38:41-57.
9. Engels, F.K., Sparreboom, A., Mathot, R.A.A., and Verweij, J. 2005. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br. J. Cancer 93:173-177.
10. Marre, F., et al. 1996. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res. 56:1296-1302.
11. Hirth, J., et al. 2000. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin. Cancer Res. 6:1255-1258.
12. Bruno, R., et al. 1998. Population pharmacokinetics / pharmacodynamics of docetaxel in phase II studies in patients with cancer. J. Clin. Oncol. 16:187-196.
13. Lin, J.H., Chiba, M., and Baillie, T.A. 1999. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev. 51:135-156.
14. Galetin, A., and Houston, J.B. 2006. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J. Pharmacol. Exp. Ther. 318:1220-1229.
15. Hall, S.D., et al. 1999. Molecular and physical mechanisms of first-pass extraction. Drug Metab. Dispos. 27:161-166.
16. Nelson, D.R., et al. 2004. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics. 14:1-18.
17. Oinonen, T., and Lindros, K.O. 1995. Hormonal regulation of the zonated expression of cytochrome P-450 3A in rat liver. Biochem. J. 309:55-61.
18. Van Herwaarden, A.E., et al. 2005. Midazolam and cyclosporin A metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metab. Dispos. 33:892-895.
19. Shou, M., et al. 1998. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics. 8:391-401.
20. Nobrega, M.A., Zhu, Y., Plajzer-Frick, I., Afzal, V., and Rubin, E.M. 2004. Megabase deletions of gene deserts result in viable mice. Nature. 431:988-993.
21. Bardelmeijer, H.A., et al. 2002. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res. 62:6158-6164.
22. Kuehl, P., et al. 2001. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27:383-391.
23. Lieb, W., et al. 2006. No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy. Clin. Sci. 111:365-372.
24. Wilkinson, G.R. 2005. Drug metabolism and variability among patients in drug response. New Engl. J. Med. 352: 2211-2221.
25. Wacher, V.J., Wu, C.-Y., and Benet, L.Z. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:129-134.
26. Jonker, J.W., et al. 2001. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22A1]). gene. Mol. Cell. Biol. 21:5471-5477.
27. Emoto, C., et al. 2000. Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. Xenobiotica. 30:943-953.
28. Kuppens, I.E., van Maanen, M.J., Rosing, H., Schellens, J.H.M., and Beijnen, J.H. 2005. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. Biomed. Chromatogr. 19:355-361.